Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study-Reference-Cited by-同舟云学术

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Published:2017-09 Issue:9 Volume:18 Page:1182-1191
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Overman Michael J,McDermott Ray,Leach Joseph L,Lonardi Sara,Lenz Heinz-Josef,Morse Michael A,Desai Jayesh,Hill Andrew,Axelson Michael,Moss Rebecca A,Goldberg Monica V,Cao Z Alexander,Ledeine Jean-Marie,Maglinte Gregory A,Kopetz Scott,André Thierry

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Multicenter retrospective analysis of metastatic CRC with high-level microsatellite instability (MSI-H);Goldstein;Ann Oncol,2014

2. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer;Koopman;Br J Cancer,2009

3. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies;Venderbosch;Clin Cancer Res,2014

4. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer;Tran;Cancer,2011

5. Genomic correlates of immune-cell infiltrates in colorectal carcinoma;Giannakis;Cell Rep,2016

Cited by 2178 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Investigating the therapeutic promise of drug-repurposed-loaded nanocarriers: A pioneering strategy in advancing colorectal cancer treatment;International Journal of Pharmaceutics;2024-10

3. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?;Critical Reviews in Oncology/Hematology;2024-10

4. Colorectal cancer: Recent advances in management and treatment;World Journal of Clinical Oncology;2024-09-24

5. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14